Iovance Biotherapeutics is a late-stage oncology company with the potential to bring the first novel autologous T cell therapy to the market for solid tumors in patients with significant unmet needs.
Iovance Biotherapeutics is a late-stage oncology company with the potential to bring the first novel autologous T cell therapy to the market for solid tumors in patients with significant unmet needs.